The MoBot Report

October 30, 2024

DENVER, Colo., Oct 30, 2024 (247marketnews.com)- MoBot’s recent alerts involved; ASP Isotopes (NASDAQ: ASPI), Tharimmune (NASDAQ: THAR), Solidion (NASDAQ: STI), MIRA (NASDAQ: MIRA), Vast (NASDAQ:VSTE), and Bright Minds (NASDAQ: DRUG).

MoBot started alerting ASP Isotopes (NASDAQ: ASPI) early in the month, on October 3, at $3.027 and today ASP Isotopes hit $9.23, just after the market open. Today, ASP Isotopes stated that TerraPower agreed to fund the construction a uranium enrichment facility capable of producing High Assay Low-Enriched Uranium (HALEU) and the future supply of HALEU, which TerraPower will purchase upon completion.

MoBot alerted Tharimmune (NASDAQ: THAR) at $2.625 after it reported receiving positive feedback at its Scientific Advice meeting with the European Medicines Agency (EMA), which included guidance on planned TH104, the Company’s lead clinical-stage candidate for moderate-to-severe pruritus in primary biliary cholangitis (PBC), Phase 2 and Phase 3 trials. Tharimmune quickly ran to $6.283, but has drifted lower since.

MoBot alerted Solidion Technology (NASDAQ: STI) at $0.489 after it reported that it was awarded a key US patent on a graphene-enabled battery fast-charging and cooling system and its battery scientists successfully developed a cost-effective strategy that allows complete charging in 5 minutes for a wide range of lithium batteries. Solidrdion quickly ran to $0.7979, but has drifted lower since.

MIRA Pharmaceuticals (NASDAQ: MIRA)  is another one that MoBot’s been alerting for about a month, when it was at $1.179, on Sept 27. MIRA has trended higher since and is running on the heels on the news that Ketamir-2, a novel oral ketamine analog, achieves 60% greater efficacy than the FDA-approved neuropathic pain treatment gabapentin in reducing chemotherapy-induced pain, building  on earlier successes across various pain models, further validating Ketamir-2’s potential to set a new standard in pain management.

Vast Renewables (NASDAQ:VSTE) announced, yesterday, signed a development services agreement with GGS Energy to pursue a commercial-scale synthetic fuels project in the Southwest United States (Project Bravo).

Bright Minds (NASDAQ: DRUG), which MoBot alerted at $1.426, on Oct 14, before it ran to a new 52-week high of $79.02, continues to trade around the $50 level, with today’s high being exactly $50.

Bright Minds (NASDAQ: DRUG) stated, last week, that it is again collaborating with Firefly Neuroscience (NASDAQ: AIFF) to thoroughly evaluate the electroencephalogram (EEG) data in Bright Minds’ BREAKTHROUGH study, an open-label Phase 2 clinical trial evaluating the safety, tolerability, and efficacy of BMB-101, in adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE).

Please go to 247marketnews.com to sign up for free MoBot alerts and view Mobot’s real time data.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (ASPI, THAR, STI, MIRA, VSTE, DRUG)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.